RxDoctor Payments Data

Guenther Koehne, MD

Medical Oncology · Miami, FLNPI 1679791818

Payments from drug & device makers

$996,963in general payments, 2019–2025

Across 190 payments — averaging $5247.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$684K
  • Bristol Myers Squibb$86K
  • Jazz Pharmaceuticals Inc.$57K
  • Karyopharm Therapeutics Inc.$41K
  • Redhill Biopharma Inc.$39K
  • ADC Therapeutics America, Inc.$37K
  • plus $54K from 15 others
$11,651in research payments, 2019–2025

Across 14 payments — averaging $832.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$11K
  • Eli Lilly$271

What the payments were for

  • Consulting fees$7,12019%
  • Speaking & faculty fees$26,13469%
  • Travel & lodging$2,2376%
  • Food & beverage$2,0846%
  • Education$990%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$996,963 in reported general payments places this provider in the 80th percentile of 507 medical oncology providers in Florida.

See all medical oncology providers in Florida

Medicare billing

Part B allowed, 2024
$13,182
Medicare patients
44
Services billed
113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →